Compare BILL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | IRON |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.6B |
| IPO Year | 2019 | 2020 |
| Metric | BILL | IRON |
|---|---|---|
| Price | $61.45 | $75.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 13 |
| Target Price | $62.93 | ★ $127.69 |
| AVG Volume (30 Days) | ★ 1.9M | 894.2K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $1,653,160,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.79 | N/A |
| P/E Ratio | $105.05 | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $31.41 | $40.00 |
| 52 Week High | $66.58 | $99.50 |
| Indicator | BILL | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 47.11 |
| Support Level | $41.09 | $73.04 |
| Resistance Level | N/A | $83.56 |
| Average True Range (ATR) | 2.73 | 3.77 |
| MACD | 1.07 | -1.17 |
| Stochastic Oscillator | 72.04 | 6.09 |
BILL Holdings Inc is the intelligent finance platform trusted by nearly half a million businesses and their accountants to manage, move, and maximize their money. It powers businesses ranging from fast-moving startups to growing companies with complex operations. It use artificial intelligence (AI) to deliver strategic finance capabilities in one integrated platform that includes accounts payable (AP), accounts receivable (AR), expenses, forecasting, procurement, and more. The company operates as one operating segment. Its products are Accounts Payable, Accounts Receivable, Accountant Console, Pay By Card, ACH Payments, International Payments, Invoicing, Approvals, Integrations, Controls, Mobile App, and Security. Its solutions are Construction, Education, Healthcare, Hospitality, etc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.